P-A drug identification program
Association will ask FDA to require marking or imprinting of each OTC drug tablet, capsule, lozenge or oral dose form with identity of medication. In the meantime, P-A has announced a voluntary industry effort. Program will help to promote added consumer awareness and aid in identification of drugs in over-dose cases, P-A says. A similar mandatory program is before the Washington state legislature. P-A is asking the state to defer the plan until a nationwide program is put into effect.
You may also be interested in...
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.